Skip to main content
PMC home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1997 Apr;73(2):110–116. doi: 10.1136/sti.73.2.110

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.

N J Bodsworth 1, R J Crooks 1, S Borelli 1, G Vejlsgaard 1, J Paavonen 1, A M Worm 1, N Uexkull 1, J Esmann 1, A Strand 1, A J Ingamells 1, A Gibb 1
PMCID: PMC1195783  PMID: 9215092

Abstract

OBJECTIVE: To compare the efficacy and safety of twice daily valaciclovir with five times daily aciclovir in the treatment of an episode of recurrent genital herpes simplex virus (HSV) infection in immunocompetent individuals. METHODS: 739 patients with a history of recurrent genital HSV infection received either oral valaciclovir (500 mg twice daily) or aciclovir (200 mg five times daily) for 5-days for treatment of their next recurrent episode in a controlled, randomised, double blind trial. Patients self initiated therapy at the first signs and/or symptoms of the HSV recurrence, then were assessed in clinic on five occasions over 7 days, and twice weekly thereafter until lesions had healed. Safety was evaluated through adverse experience reports and haematology and biochemistry monitoring. RESULTS: No significant differences were detected between valaciclovir and aciclovir for the primary endpoint, the duration of all signs and symptoms which included lesion healing and pain/discomfort. The hazard ratio [95% confidence interval] for valaciclovir v aciclovir was 0.93 [0.79, 1.08]. Lesion healing time was similar in each treatment group (hazard ratio valaciclovir v aciclovir 0.96 [0.80, 1.14]). The odds ratio of valaciclovir v aciclovir in preventing the development of vesicular/ulcerative lesions was 1.08 [0.82, 1.42]. Percentages of patients in whom all HSV cultures were negative were similar in the valaciclovir and aciclovir groups at 59% and 54% respectively; for patients having equal to or more than one positive culture result after treatment initiation, cessation of virus shedding was similarly rapid for the two treatments (hazard ratio 0.98 [0.75, 1.27]). The safety profiles of valaciclovir and aciclovir were comparable with adverse experiences being infrequent and generally mild. CONCLUSION: This study has demonstrated that valaciclovir 500 mg twice daily is equivalent in efficacy to aciclovir 200 mg five times daily as episodic treatment of recurrent genital HSV infection. Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much more convenient twice daily dosing regimen.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Corey L., Mindel A., Fife K. H., Sutherland S., Benedetti J., Adler M. W. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex Transm Dis. 1985 Oct-Dec;12(4):215–218. doi: 10.1097/00007435-198510000-00009. [DOI] [PubMed] [Google Scholar]
  2. Goldberg L. H., Kaufman R., Conant M. A., Sperber J., Allen M. L., Illeman M., Chapman S. Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety. J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):256–264. doi: 10.1016/s0190-9622(86)70165-5. [DOI] [PubMed] [Google Scholar]
  3. Goldberg L. H., Kaufman R., Conant M. A., Sperber J., Allen M. L., Illeman M., Donohew P. S., Chapman S. Episodic twice-daily treatment for recurrent genital herpes. Am J Med. 1988 Aug 29;85(2A):10–13. [PubMed] [Google Scholar]
  4. Goldberg L. H., Kaufman R., Kurtz T. O., Conant M. A., Eron L. J., Batenhorst R. L., Boone G. S. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol. 1993 May;129(5):582–587. [PubMed] [Google Scholar]
  5. Johnson R. E., Nahmias A. J., Magder L. S., Lee F. K., Brooks C. A., Snowden C. B. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989 Jul 6;321(1):7–12. doi: 10.1056/NEJM198907063210102. [DOI] [PubMed] [Google Scholar]
  6. Mattison H. R., Reichman R. C., Benedetti J., Bolgiano D., Davis L. G., Bailey-Farchione A., Remington M., Winter C., Corey L. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. Am J Med. 1988 Aug 29;85(2A):20–25. [PubMed] [Google Scholar]
  7. Mindel A., Weller I. V., Faherty A., Sutherland S., Fiddian A. P., Adler M. W. Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin Med. 1986 Feb;62(1):28–32. doi: 10.1136/sti.62.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nahmias A. J., Lee F. K., Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19–36. [PubMed] [Google Scholar]
  9. Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
  10. O'Brien J. J., Campoli-Richards D. M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233–309. doi: 10.2165/00003495-198937030-00002. [DOI] [PubMed] [Google Scholar]
  11. Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
  12. Ruhnek-Forsbeck M., Sandström E., Andersson B., Eriksson G., Hersle K., Lövhagen G. B., Mobacken H., Hillström L., Svensson L. Treatment of recurrent genital herpes simplex infections with oral acyclovir. J Antimicrob Chemother. 1985 Nov;16(5):621–628. doi: 10.1093/jac/16.5.621. [DOI] [PubMed] [Google Scholar]
  13. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995 Dec;39(12):2759–2764. doi: 10.1128/aac.39.12.2759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
  15. Tilson H. H., Engle C. R., Andrews E. B. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol. 1993;Suppl 1:67–73. doi: 10.1002/jmv.1890410513. [DOI] [PubMed] [Google Scholar]
  16. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
  17. Whatley J. D., Thin R. N. Episodic acyclovir therapy to abort recurrent attacks of genital herpes simplex infection. J Antimicrob Chemother. 1991 May;27(5):677–681. doi: 10.1093/jac/27.5.677. [DOI] [PubMed] [Google Scholar]
  18. Whitley R. J., Gnann J. W., Jr Acyclovir: a decade later. N Engl J Med. 1992 Sep 10;327(11):782–789. doi: 10.1056/NEJM199209103271108. [DOI] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES